Screener
Rigel Pharmaceuticals RIGL Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash (used in) provided by financing activities | (10,919) | 484 |
| Net decrease in cash, cash equivalents and restricted cash | (16,169) | (10,961) |
| Cash, cash equivalents, and restricted cash at beginning of period | 40,637 | 56,746 |
| Cash, cash equivalents, and restricted cash at end of period | $24,468 | $45,785 |
| Supplemental disclosure of cash flow information | ||
| Interest paid | $1,320 | $1,653 |
| Increase in right-of-use assets and lease liabilities | — | $1,220 |
| Acquisition-related liabilities | $5,000 | $5,000 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's cash & equivalents?
- Rigel Pharmaceuticals (RIGL) reported cash & equivalents of $24.47M in Q1 2026.
- How has Rigel Pharmaceuticals's cash & equivalents changed year-over-year?
- Rigel Pharmaceuticals's cash & equivalents decreased by 46.6% year-over-year, from $45.79M to $24.47M.
- What is the long-term trend for Rigel Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's cash & equivalents has grown at a 6.0% compound annual growth rate (CAGR), from $30.37M to $40.64M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Rigel Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude